HOW CHINA USES BIG DATA TO PREDICT
CANCER PROGRESSION AND TREATMENT RESPONSE
China has built one of the world's largest data-driven oncology ecosystems, combining high patient volumes, genomic testing, AI imaging, digital pathology and clinical trial networks.
analyticsAt a Glance
- check_circleCombines imaging, pathology, genomics, blood markers and real-world outcomes at scale โ not single-factor predictions.
- check_circleMost useful in advanced, recurrent or treatment-resistant cancer with complex biology.
- check_circleAI supports oncologists โ it does not replace clinical judgement or promise a response.
- check_circleComprehensive NGS and liquid biopsy are standard at major Chinese cancer centres.
How Big Data Helps Predict Progression and Response
By comparing a patient with many similar cases, data analysis can flag features linked to higher progression risk and estimate whether a patient is likely to respond to a particular treatment. These remain estimates, not certainties.
AI Radiology
Studies CT, MRI and PET-CT to assess tumour size, growth pattern, response and recurrence. Radiomics extracts subtle imaging features invisible to the human eye.
AI Pathology
Digital pathology with machine learning helps assess tumour grade, immune-cell infiltration, necrosis and biomarker patterns from scanned tissue slides.
Genomic Data Analysis
Helps interpret large NGS panels by highlighting actionable mutations, resistance pathways and possible trial matches โ more systematically than manual review alone.
Liquid Biopsy and Trial Matching
Circulating tumour DNA detects mutations, monitors response and identifies resistance earlier. AI-based trial matching compares patient profiles against eligibility criteria systematically.
Where Big Data Is Most Useful by Cancer Type
Data-driven oncology is relevant across many cancers but is most helpful where biology is complex and several treatment pathways exist.
Lung Cancer
Integrating mutation testing (EGFR, ALK, ROS1, MET, RET, KRAS, HER2), resistance mechanisms, PD-L1 status, imaging progression and targeted therapy sequencing across multiple lines.
Gastric and GEJ Cancer
Using HER2, CLDN18.2, FGFR2b, MSI, PD-L1 and EBV status alongside prior chemotherapy response to guide immunotherapy, targeted agents, ADCs and CAR-T trial selection.
Liver Cancer
Combining liver function, tumour burden, AFP, vascular invasion and response to TACE, immunotherapy, targeted therapy or ablation โ all relevant to sequencing decisions.
Colorectal and Breast Cancer
Weighing RAS, BRAF, MSI, HER2 and tumour sidedness for colorectal; predicting response across hormone-positive, HER2-positive and triple-negative disease using receptor status and treatment history.
How CancerFax Helps
A structured pathway to data-informed treatment planning and trial options.
- 1
Report Collection and Case Understanding
Diagnosis, treatment history, current disease status and goals are reviewed to understand the full picture.
- 2
Testing and Data Review
Gaps such as missing NGS, biomarker testing or imaging are identified, and interpretation of molecular and imaging data is arranged.
- 3
Second Opinion and Clinical Suitability
Reports are shared with oncology teams that use imaging, pathology, genomics and real-world experience to assess realistic options.
- 4
Treatment and Trial Mapping
Relevant pathways and trials in China and other countries are matched against the patient's biomarkers and prior treatment.
- 5
Planning and Coordination
Guidance on likely pathway, timelines, cost factors, logistics, interpretation, hospital communication and follow-up.
Frequently Asked Questions
Big Data in Cancer Prediction
Can big data tell me whether a treatment will work?
No. Big data and AI estimate probability by comparing your profile with many similar cases. They can suggest which options are more or less likely to help, but cannot promise a response. Every recommendation still needs review by an experienced oncologist who considers your full clinical picture.
Do I need NGS or liquid biopsy before this kind of review?
Comprehensive testing makes a data-informed review far more useful because many predictions depend on biomarkers and mutations. If you do not yet have results, a case can still be reviewed, and the team can advise which tests would add the most value.
Does AI replace the oncologist in China?
No. AI and big data are decision-support tools that help analyse imaging, pathology and genomic data at scale, but the treating oncologist interprets the results and makes the final plan. Responsible centres use these tools to strengthen expert judgement, not to override it.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Exploring Data-Driven Cancer Care in China?
Share your pathology, imaging and molecular reports. Our clinical team will identify whether data-informed treatment planning in China offers a meaningful advantage for your specific cancer and disease status.
This information is for patient education and navigation support only. All treatment decisions must be made in consultation with a qualified oncologist.